Version Française

Contribute to the regulation by quality and efficiency

Search

impression
TRANSPARENCY COMMITTEE OPINION

ZONTIVITY (vorapaxar), platelet aggregation inhibitor

Active substance (DCI)
  • vorapaxar
CARDIOLOGY - New medicinal product

Reason for request
Inclusion

Date 18 November 2015

Indications concerned
-

Insufficient actual benefit, in combination with acetylsalicylic acid and where appropriate with clopidogrel, in the reduction of atherothrombotic events in adult patients with a history of myocardial infarction

  

  • ZONTIVITY has Marketing Authorisation, in combination with acetylsalicylic acid (ASA) and where appropriate with clopidogrel, in the reduction of atherothrombotic events in adult patients with a history of myocardial infarction (MI).
  • Its actual benefit is insufficient for reimbursement by National Health Insurance because of:
  • a minor clinical added value in terms of morbidity and the lack of demonstrated efficacy in terms of mortality;
  • and the greater occurrence of haemorrhagic events with the therapeutic strategy vorapaxar + ASA ± clopidogrel versus the strategy ASA ± clopidogrel.

 

 


Actual benefit

Insuffisant

-


Therapeutic use

-

Ce produit a fait l'objet d'un avis d'efficience rendu par la commission évlauation économique et de santé publique

le 13 octobre 2015

Documents

Economic analysis

English version

ATC Code
  • B01AC26
Laboratory / Manufacturer
MSD FRANCE

Presentation

-

Posted on Dec 10 2015